PMID- 32243377
OWN - NLM
STAT- MEDLINE
DCOM- 20200408
LR  - 20221207
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 14
DP  - 2020 Apr
TI  - Efficacy and tolerability of paroxetine in adults with social anxiety disorder: A 
      meta-analysis of randomized controlled trials.
PG  - e19573
LID - 10.1097/MD.0000000000019573 [doi]
LID - e19573
AB  - OBJECTIVE: The present study aimed to estimate the comprehensive efficacy and 
      tolerability of paroxetine in adult patients with social anxiety disorder (SAD). 
      METHODS: We conducted a comprehensive literature review of the PubMed, Embase, 
      Cochrane Central Register of Controlled Trials, Web of Science, and 
      ClinicalTrials databases for eligible randomized controlled trials (RCTs). The 
      efficacy outcome was the mean change of different kinds of scale scores as well 
      as response and remission rates. The secondary outcome was tolerability, defined 
      as the discontinuation rate and the incidence of adverse events (AEs). RESULTS: 
      Our meta-analysis included 13 RCTs. Mean changes in the Liebowitz Social Anxiety 
      Scale (LSAS) total score, fear and avoidance subscale of LSAS scores were all 
      significantly greater in patients with SAD that received paroxetine compared to 
      those received placebo (total: MD = 13.46, 95%CI 10.59-16.32, P < .00001; fear: 
      MD = 6.76, 95%CI 4.89-8.62, P < .00001; avoidance: MD = 6.54, 95%CI 4.63-8.45, 
      P < .00001). Response and remission rates were both significantly greater in 
      patients with SAD that received paroxetine compared to those received placebo 
      (response: OR = 3.02, 95%CI 2.30-3.97, P < .00001; remission: OR = 3.14, 95%CI 
      2.25-4.39, P < .00001). There was no significant difference in discontinuation 
      rate due to any reason between two groups (OR = 1.06, 95%CI 0.81-1.39, P = .65). 
      Discontinuation rate due to AEs was higher in paroxetine than placebo group 
      (OR = 3.41, 95%CI 2.45-4.72, P < .00001) whereas the rate due to lack of efficacy 
      was higher in placebo as compared with paroxetine group (OR = 0.14, 95%CI 
      0.09-0.22, P < .00001). The incidence of any AE was significantly increased in 
      patients that received paroxetine (OR = 1.83, 95%CI 1.43-2.35, P < .00001). 
      CONCLUSION: Paroxetine was an effective and well-tolerated treatment option for 
      adult patients with SAD.
FAU - Li, Xinyuan
AU  - Li X
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, P.R. China.
FAU - Hou, Yanbo
AU  - Hou Y
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, P.R. China.
FAU - Su, Yingying
AU  - Su Y
AD  - School of Public Health, University of Saskatchewan, Saskatoon, Saskatchewan, 
      Canada.
FAU - Liu, Hongping
AU  - Liu H
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, P.R. China.
FAU - Zhang, Beilin
AU  - Zhang B
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, P.R. China.
FAU - Fang, Shaokuan
AU  - Fang S
AD  - Department of Neurology, Neuroscience Centre, The First Teaching Hospital of 
      Jilin University, Changchun, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 41VRH5220H (Paroxetine)
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - Paroxetine/*therapeutic use
MH  - Phobia, Social/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Selective Serotonin Reuptake Inhibitors/*therapeutic use
MH  - Treatment Outcome
PMC - PMC7220791
COIS- The authors have no conflict of interest to disclose.
EDAT- 2020/04/04 06:00
MHDA- 2020/04/09 06:00
PMCR- 2020/04/03
CRDT- 2020/04/04 06:00
PHST- 2020/04/04 06:00 [entrez]
PHST- 2020/04/04 06:00 [pubmed]
PHST- 2020/04/09 06:00 [medline]
PHST- 2020/04/03 00:00 [pmc-release]
AID - 00005792-202004030-00022 [pii]
AID - MD-D-18-08409 [pii]
AID - 10.1097/MD.0000000000019573 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Apr;99(14):e19573. doi: 10.1097/MD.0000000000019573.